TLSI
$4.02
TriSalus Life Sciences, Inc.
Recent News
Canaccord Lowers its Price Target on TriSalus Life Sciences, Inc. (TLSI) to $7 from $12 and Maintains a Buy Rating
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) is among the 11 Fastest Growing Penny Stocks to Buy Right Now. On March 6, 2026, Canaccord analyst William Plovanic lowered the price target on TriSalus Life Sciences, Inc. (NASDAQ:TLSI) to $7 from $12 previously and maintained a Buy rating. William Plovanic said Q4 results came in line with the […]
TriSalus Life Sciences, Inc. Q4 2025 Earnings Call Summary
Moby summary of TriSalus Life Sciences, Inc.'s Q4 2025 earnings call
TriSalus Life Sciences Q4 Earnings Call Highlights
TriSalus Life Sciences (NASDAQ:TLSI) reported fourth-quarter and full-year 2025 results that management characterized as “strong,” driven by growth in its TriNav product suite and broader adoption of its Pressure-Enabled Drug Delivery (PEDD) platform beyond liver-directed procedures. Revenue growth
TriSalus Life Sciences Inc (TLSI) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ...
TriSalus Life Sciences Inc (TLSI) reports a 60% revenue increase and strategic growth plans, despite facing operational losses and delayed clinical data releases.
TriSalus (TLSI) Q4 2025 Earnings Call Transcript
Need a quote from a Motley Fool analyst? Ms. Szela will provide an overview of the company's fourth quarter results and strategy for the balance of the year, and then David will review the financial results for the quarter in detail.